# Fibrinogen Replacement to Prevent Intracranial Haemorrhage in Ischemic Stroke Patients After Thrombolysis (FibER)

Study · id `cardio:ct-nct05300672` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT05300672](<https://clinicaltrials.gov/study/NCT05300672>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT05300672

Browse, organ or system: Brain  
Browse, condition area: Stroke  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 207 participants.

## Technical summary

Registry record NCT05300672. Randomized; no masking; primary purpose treatment. Start 2022-02-08 (actual); primary completion 2024-12-31 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 207 participants (enrolled count; ClinicalTrials.gov record NCT05300672, source copy `cardio:ctgov-nct05300672-2025-08-01`, retrieved 2026-10-26)
- Started: 2022-02-08 (actual) (ClinicalTrials.gov record NCT05300672, source copy `cardio:ctgov-nct05300672-2025-08-01`, retrieved 2026-10-26)
- Primary completion: 2024-12-31 (actual) (ClinicalTrials.gov record NCT05300672, source copy `cardio:ctgov-nct05300672-2025-08-01`, retrieved 2026-10-26)
- Completion: 2025-05-27 (actual) (ClinicalTrials.gov record NCT05300672, source copy `cardio:ctgov-nct05300672-2025-08-01`, retrieved 2026-10-26)
- Countries: Italy (ClinicalTrials.gov record NCT05300672, source copy `cardio:ctgov-nct05300672-2025-08-01`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct05300672-2025-08-01`, retrieved 2026-10-26)

## The registry's words

- Brief title: Fibrinogen Replacement to Prevent Intracranial Haemorrhage in Ischemic Stroke Patients After Thrombolysis (FibER)
- Acronym: FibER
- Condition: Intracranial Hemorrhages
- Condition: Ischemic Stroke
- Intervention (Drug): fibrinogen infusion
- Lead sponsor: Azienda Usl di Bologna
- Lead sponsor class: OTHER\_GOV
- Collaborator: Ministero della Salute, Italy
- Collaborator class: OTHER

## Connected pages

- Registry condition terms include this condition: Ischemic stroke (`cardio:ischemic-stroke`)
- Registry condition terms include this condition: Stroke (`core:stroke`)
- Registry lists this organization as the lead sponsor: Azienda Usl di Bologna (`cardio:org-azienda-usl-di-bologna`)

## Provenance

Content hash: c9ac5fd90761cfd8137214b20330a657b69fbd34dd8cb25337fddba34f30f80c
Last substantive edit: 2026-11-18
Evidence last checked: Not recorded
